伊立替康与紫杉醇联合顺铂在宫颈癌新辅助化疗中的比较

目的 对比观察伊立替康联合顺铂（IP） 与紫杉醇联合顺铂（TP） 在宫颈癌新辅助化疗中的疗效和毒副作用.方法 50例Ⅰb2～Ⅱb期宫颈癌患者,随机分为两组,A 组（25 例） 行IP方案化疗两周期,B 组（25例） 行TP方案两周期,比较两组疗效及不良反应.结果 A、B 组组两周期化疗后有效率、不良反应、病检比较差异有统计学意义（P＜0.05）.结论 紫杉醇联合顺铂是宫颈癌较为理想的新辅助化疗方案.

Study of irinotecan-cisplatin versus paclitaxel-cisplatin in neoadjuvant chemotherapy for cervical cancer

Objective To evaluate and compare the efficacy and toxicity of irinoteean and cisplatin （IP） versus paclitaxel plus eisplatin （TP） in neoadjuvant chemotherapy for cervical cancer. Methods All 50 patients with stage I b2 ~ II b carcinoma of cervix were randomly divided into two groups, group A（25patients） underwent two cycles of IP chemotherapy,while group B （ 25 patients） underwent two cycles of rip chemotherapy, and the efficacy and toxicity were compared. Results After two cycles of chemotherapy, efficiency,pathologic examination showed statistical significant difference. Conclusion Paelitaxel plus cisplatin is more ideal neoadjuvant chemotherapy for cervical cancer.